Ginkgo, hunting for biotech platforms that ‘collect dust,’ scoops up AAV gene therapy capsid specialist

(April 5, 2023) | By Annalee Armstrong.

Ginkgo Bioworks doesn’t want the biotech industry’s therapies. But it does want the platforms that create them, which is why the cell programming company is buying up StrideBio for its gene therapy intellectual property.

The acquisition will bring StrideBio’s adeno-associated virus (AAV) capsid discovery and engineering platform called STRIVE under Ginkgo’s wing, including a library of well-tested and advanced capsids that could provide fodder for future partnerships. The deal is part of Ginkgo’s broader M&A strategy to pick up new, complimentary biotech platforms.